drug
polatuzumab vedotin
Marketedupdated 5mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
DLBCL
all catalysts(4)
approval · 4
Jun 10, 2019
approval
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Sep 18, 2020
approval
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Apr 19, 2023
approval
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Mar 18, 2026
approval
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Trials studying polatuzumab vedotin
- phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- phase1A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
- phase2TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
- phase1Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
- phase2A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- phase3A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- —A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
- phase1Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
News(2)
- Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBioThrough its DualityBio deal, Roche's Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.biospace · 1mo ago
- Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onRoche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…biospace · 2mo ago
Data sources
last refreshed 41m ago
Found something off?
comments(0)
5-min edit window · permanent after that